Vaxil Bio Ltd.
VXLLF
$0.0035
$0.001575.00%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 65.69% | -36.64% | -41.37% | -163.00% | -37.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 69.92% | -62.12% | -53.46% | -117.88% | -76.90% |
| Operating Income | -69.92% | 62.12% | 53.46% | 117.88% | 76.90% |
| Income Before Tax | -71.77% | 62.12% | 53.46% | 114.98% | 80.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -71.77% | 62.12% | 53.46% | 114.98% | 80.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -71.77% | 62.12% | 53.46% | 114.98% | 80.38% |
| EBIT | -69.92% | 62.12% | 53.46% | 117.88% | 76.90% |
| EBITDA | -- | -- | -- | 118.20% | 77.28% |
| EPS Basic | -50.00% | 57.14% | 57.14% | 111.11% | 75.00% |
| Normalized Basic EPS | -100.00% | 50.00% | 50.00% | 116.67% | 80.00% |
| EPS Diluted | -50.00% | 57.14% | 57.14% | 111.11% | 75.00% |
| Normalized Diluted EPS | -100.00% | 50.00% | 50.00% | 116.67% | 80.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
